NanoKnife System

DEVICE4 trials

Sponsors

University Health Network, Toronto, Angiodynamics, Inc., Memorial Sloan Kettering Cancer Center

Conditions

Pancreatic Ductal AdenocarcinomaProstate CancerStage III Pancreatic Cancer

Phase 3

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

Active, not recruitingNCT03899636

Angiodynamics, Inc.Stage III Pancreatic Cancer

Start: 2021-02-23End: 2025-04-30Target: 528Updated: 2025-02-12

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

RecruitingNCT07548164

Memorial Sloan Kettering Cancer CenterProstate Cancer

Start: 2026-04-16End: 2029-04-16Target: 224Updated: 2026-09-18

Unknown Phase

A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer

CompletedNCT03257150

University Health Network, TorontoPancreatic Ductal Adenocarcinoma

Start: 2017-09-22End: 2022-07-14Updated: 2022-08-11

A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

Active, not recruitingNCT03899649

Angiodynamics, Inc.Stage III Pancreatic Cancer

Start: 2019-05-08End: 2025-04-30Target: 532Updated: 2025-02-12

Related Papers

Effectiveness and safety of irreversible electroporation when used for the ablation of stage 3 pancreatic adenocarcinoma: A registry study (DIRECT).

Journal of Clinical Oncology2024-06-01

Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols.

2021-07-0710 citations

Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial.

2021-04-2916 citations